tetano
Editor, Senior Moderator
Int J Rheum Dis
. 2024 May;27(5):e15178.
doi: 10.1111/1756-185X.15178. Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group
Russka Shumnalieva[SUP] 1 [/SUP], Naveen Ravichandran[SUP] 2 [/SUP], Jennifer Hannah[SUP] 3 [/SUP], Mahnoor Javaid[SUP] 4 [/SUP], Naitica Darooka[SUP] 5 [/SUP], Debaditya Roy[SUP] 6 [/SUP], Daniel E Gonzalez[SUP] 7 [/SUP], Tsvetelina Velikova[SUP] 8 [/SUP], Marcin Milchert[SUP] 9 [/SUP], Masataka Kuwana[SUP] 10 [/SUP], Mrudula Joshi[SUP] 11 [/SUP], Abraham Edgar Gracia-Ramos[SUP] 12 [/SUP], Peter Boyd[SUP] 13 [/SUP], Praggya Yaadav[SUP] 14 [/SUP], Karen Cheng[SUP] 15 [/SUP], Linda Kobert[SUP] 16 [/SUP], Lorenzo Cavagna[SUP] 17 [/SUP], Parikshit Sen[SUP] 18 [/SUP], Jessica Day[SUP] 19 20 21 [/SUP], Ashima Makol[SUP] 22 [/SUP], Carlos Enrique Toro Gutiérrez[SUP] 23 [/SUP], Carlo V Caballero-Uribe[SUP] 24 [/SUP], Sreoshy Saha[SUP] 25 [/SUP], Ioannis Parodis[SUP] 26 27 [/SUP], Dzifa Dey[SUP] 28 [/SUP], Elena Nikiphorou[SUP] 29 30 [/SUP], Oliver Distler[SUP] 31 [/SUP], Esha Kadam[SUP] 5 [/SUP], Ai Lyn Tan[SUP] 32 33 [/SUP], Samuel Katsuyuki Shinjo[SUP] 34 [/SUP], Nelly Ziade[SUP] 35 36 [/SUP], Johannes Knitza[SUP] 37 38 [/SUP], Hector Chinoy[SUP] 39 40 41 [/SUP], Rohit Aggarwal[SUP] 42 [/SUP], Vikas Agarwal[SUP] 2 [/SUP], Latika Gupta[SUP] 39 43 [/SUP]; COVAD Study Group
Collaborators, Affiliations
Background: Despite the overall safety and efficacy of COVID-19 vaccinations, rare cases of systemic autoimmune diseases (SAIDs) have been reported post-vaccination. This study used a global survey to analyze SAIDs in susceptible individuals' post-vaccination.
Methods: A cross-sectional study was conducted among participants with self-reported new-onset SAIDs using the COVID-19 Vaccination in Autoimmune Diseases (COVAD) 2 study dataset-a validated, patient-reported e-survey-to analyze the long-term safety of COVID-19 vaccines. Baseline characteristics of patients with new-onset SAIDs and vaccinated healthy controls (HCs) were compared after propensity score matching based on age and sex in a 1:4 ratio.
Results: Of 16 750 individuals, 74 (median age 52 years, 79.9% females, and 76.7% Caucasians) had new-onset SAID post-vaccination, mainly idiopathic inflammatory myopathies (IIMs) (n = 23, 31.51%), arthritis (n = 15; 20.53%), and polymyalgia rheumatica (PMR) (n = 12, 16.40%). Higher odds of new-onset SAIDs were noted among Caucasians (OR = 5.3; 95% CI = 2.9-9.7; p < .001) and Moderna vaccine recipients (OR = 2.7; 95% CI = 1.3-5.3; p = .004). New-onset SAIDs were associated with AID multimorbidity (OR = 1.4; 95% CI = 1.1-1.7; p < .001), mental health disorders (OR = 1.6; 95% CI = 1.3-1.9; p < .001), and mixed race (OR = 2.2; 95% CI = 1.2-4.2; p = .010), where those aged >60 years (OR = 0.6; 95% CI = 0.4-0.8; p = .007) and from high/medium human development index (HDI) countries (compared to very high HDI) reported fewer events than HCs.
Conclusion: This study reports a low occurrence of new-onset SAIDs following COVID-19 vaccination, primarily IIMs, PMR, and inflammatory arthritis. Identified risk factors included pre-existing AID multimorbidity, mental health diseases, and mixed race. Revaccination was well tolerated by most patients; therefore, we recommend continuing COVID-19 vaccination in the general population. However, long-term studies are needed to understand the autoimmune phenomena arising post-vaccination.
Keywords: COVID‐19; SAIDs; autoimmune diseases; idiopathic inflammatory myopathies; vaccination.
. 2024 May;27(5):e15178.
doi: 10.1111/1756-185X.15178. Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group
Russka Shumnalieva[SUP] 1 [/SUP], Naveen Ravichandran[SUP] 2 [/SUP], Jennifer Hannah[SUP] 3 [/SUP], Mahnoor Javaid[SUP] 4 [/SUP], Naitica Darooka[SUP] 5 [/SUP], Debaditya Roy[SUP] 6 [/SUP], Daniel E Gonzalez[SUP] 7 [/SUP], Tsvetelina Velikova[SUP] 8 [/SUP], Marcin Milchert[SUP] 9 [/SUP], Masataka Kuwana[SUP] 10 [/SUP], Mrudula Joshi[SUP] 11 [/SUP], Abraham Edgar Gracia-Ramos[SUP] 12 [/SUP], Peter Boyd[SUP] 13 [/SUP], Praggya Yaadav[SUP] 14 [/SUP], Karen Cheng[SUP] 15 [/SUP], Linda Kobert[SUP] 16 [/SUP], Lorenzo Cavagna[SUP] 17 [/SUP], Parikshit Sen[SUP] 18 [/SUP], Jessica Day[SUP] 19 20 21 [/SUP], Ashima Makol[SUP] 22 [/SUP], Carlos Enrique Toro Gutiérrez[SUP] 23 [/SUP], Carlo V Caballero-Uribe[SUP] 24 [/SUP], Sreoshy Saha[SUP] 25 [/SUP], Ioannis Parodis[SUP] 26 27 [/SUP], Dzifa Dey[SUP] 28 [/SUP], Elena Nikiphorou[SUP] 29 30 [/SUP], Oliver Distler[SUP] 31 [/SUP], Esha Kadam[SUP] 5 [/SUP], Ai Lyn Tan[SUP] 32 33 [/SUP], Samuel Katsuyuki Shinjo[SUP] 34 [/SUP], Nelly Ziade[SUP] 35 36 [/SUP], Johannes Knitza[SUP] 37 38 [/SUP], Hector Chinoy[SUP] 39 40 41 [/SUP], Rohit Aggarwal[SUP] 42 [/SUP], Vikas Agarwal[SUP] 2 [/SUP], Latika Gupta[SUP] 39 43 [/SUP]; COVAD Study Group
Collaborators, Affiliations
- PMID: 38742751
- DOI: 10.1111/1756-185X.15178
Background: Despite the overall safety and efficacy of COVID-19 vaccinations, rare cases of systemic autoimmune diseases (SAIDs) have been reported post-vaccination. This study used a global survey to analyze SAIDs in susceptible individuals' post-vaccination.
Methods: A cross-sectional study was conducted among participants with self-reported new-onset SAIDs using the COVID-19 Vaccination in Autoimmune Diseases (COVAD) 2 study dataset-a validated, patient-reported e-survey-to analyze the long-term safety of COVID-19 vaccines. Baseline characteristics of patients with new-onset SAIDs and vaccinated healthy controls (HCs) were compared after propensity score matching based on age and sex in a 1:4 ratio.
Results: Of 16 750 individuals, 74 (median age 52 years, 79.9% females, and 76.7% Caucasians) had new-onset SAID post-vaccination, mainly idiopathic inflammatory myopathies (IIMs) (n = 23, 31.51%), arthritis (n = 15; 20.53%), and polymyalgia rheumatica (PMR) (n = 12, 16.40%). Higher odds of new-onset SAIDs were noted among Caucasians (OR = 5.3; 95% CI = 2.9-9.7; p < .001) and Moderna vaccine recipients (OR = 2.7; 95% CI = 1.3-5.3; p = .004). New-onset SAIDs were associated with AID multimorbidity (OR = 1.4; 95% CI = 1.1-1.7; p < .001), mental health disorders (OR = 1.6; 95% CI = 1.3-1.9; p < .001), and mixed race (OR = 2.2; 95% CI = 1.2-4.2; p = .010), where those aged >60 years (OR = 0.6; 95% CI = 0.4-0.8; p = .007) and from high/medium human development index (HDI) countries (compared to very high HDI) reported fewer events than HCs.
Conclusion: This study reports a low occurrence of new-onset SAIDs following COVID-19 vaccination, primarily IIMs, PMR, and inflammatory arthritis. Identified risk factors included pre-existing AID multimorbidity, mental health diseases, and mixed race. Revaccination was well tolerated by most patients; therefore, we recommend continuing COVID-19 vaccination in the general population. However, long-term studies are needed to understand the autoimmune phenomena arising post-vaccination.
Keywords: COVID‐19; SAIDs; autoimmune diseases; idiopathic inflammatory myopathies; vaccination.